Send us a text

Imagine transforming a days-long pathology process into minutes while maintaining or improving diagnostic accuracy. That's exactly what Optiscan Imaging is accomplishing with their groundbreaking miniaturised confocal end microscopy technology.

Dr Camile Farah, CEO and Managing Director of Optiscan, returns to the podcast to unveil Inform – their revolutionary digital pathology device designed specifically for pathologists and pathology labs. This innovative technology captures microscopic-grade images in real-time at 1,000 times the resolution of standard medical imaging, dramatically streamlining workflows between surgeons and pathologists while slashing diagnostic waiting times from days to minutes.

What truly sets Optiscan's approach apart is their comprehensive cloud-based telepathology platform. This system enables surgeons in Melbourne to collaborate instantly with pathologists in Arizona while the patient remains on the operating table. For rural and remote areas, this technology eliminates the need for on-site specialists, democratising access to world-class pathology services regardless of location.

Ready to explore the future of medical imaging? Listen now and discover how Australian innovation is transforming global healthcare one microscopic image at a time.

Send us a text

Fascinating breakthroughs in sustainable construction and climate technology take centre stage as James Marsh, CEO of Zeotech Limited, unveils the company's game-changing innovations. The conversation explores how Zeotech's AusPozz™ product is redefining possibilities in low-carbon concrete, with commercial demonstrations confirming its ability to replace up to 40% of cement while delivering superior strength and dramatically reduced shrinkage.

What makes this technology truly revolutionary is its versatility and comprehensive performance profile. Beyond simple cement replacement, AusPozz™ outperforms expensive additives like silica fume while eliminating the need for various chemical additives that typically address concrete issues like cracking and bleeding. This exceptional value proposition has attracted partnerships with construction giants including Holcim, with strategic agreements positioning Zeotech for seaborne distribution to Sydney and Melbourne concrete markets, as well as global opportunities through Gladstone Ports Corporation's deepwater facilities.

The conversation takes an exciting turn as Marsh details their second horizon: zeolite-based methane remediation technology showing 70-85% efficiency in capturing this potent greenhouse gas. With their pre-feasibility study nearing completion and their current resource representing just 5% of available exploration area, Zeotech stands at the threshold of significant growth. Dive into this episode to discover how Australian innovation is tackling two of our most pressing environmental challenges – carbon-intensive construction and methane emissions – with solutions that don't just match industry standards but dramatically exceed them. Ready to understand the future of sustainable materials? Listen now and gain insights into technology that leading industry experts are calling "a genuine game-changer."

Send us a text

Steve Lydeamore, CEO of Immuron Limited, takes us behind the scenes of one of Australia's most innovative biopharmaceutical companies. What makes this Melbourne-based biotech unique is their dual focus—a thriving commercial product alongside a promising technology platform targeting infectious diseases.

The spotlight falls on Travelan, Immuron's preventative treatment for traveller's diarrhoea that has experienced phenomenal growth. After sales plummeted to near-zero during the pandemic, the company has ssen a remarkable turnaround from $145,000 to over $5.3 million in less than a year. This success story involved strengthening pharmacy distribution networks across Australia and Canada while leveraging Amazon as their primary channel in the US market. As international travel rebounds, particularly to high-risk regions like Bali and Vietnam, Travelan's unique preventative approach—"nobody wants to get it"—positions it perfectly for continued growth.